•
Sanofi (EPA: SAN), a leading French pharmaceutical company, has entered into a strategic agreement with Orano Med, a subsidiary of the French Orano Group, to enhance the development of next-generation radioligand medicines. The collaboration aims to accelerate the growth of radioligand therapies (RLTs) based on lead-212 (212Pb) alpha-emitting isotopes, which…